| Bioactivity | Propanidid (Sombrevin; Fabantol) is a γ-aminobutyric acid type A (GABAA) receptor agonist and a short-acting non-barbiturate general anesthetic agent. Propanidid can decrease the arterial pressure[1][2]. |
| Target | GABAA receptor |
| In Vivo | Propanidid (Sombrevin) (3-5 mg/kg; injected into the femoral vein; single dosage) changes the orientation tuning of 58 visual cortex neurons[3]. Animal Model: |
| Name | Propanidid |
| CAS | 1421-14-3 |
| Formula | C18H27NO5 |
| Molar Mass | 337.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Cenani A, et al. In vitro and in vivo GABAA Receptor Interaction of the Propanidid Metabolite 4-(2-[Diethylamino]-2-Oxoethoxy)-3-Methoxy-Benzeneacetic Acid. Pharmacology. 2019;103(1-2):10-16. [2]. Orko R. Anaesthesia for cardioversion: a comparison of diazepam, thiopentone and propanidid. Br J Anaesth. 1976 Mar;48(3):257-62. [3]. Lazareva NA, et al. The effect of sombrevin on the orientation adjustment of the visual cortex neurons in the cat. Neirofiziologiia. 1989;21(6):812-20. |